MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

PEXIVAS trial

  • Home
  • PEXIVAS trial
Predicting Two-Year Relapse Risk in ANCA-Associated Vasculitis: Insights from the PEXIVAS Trial
Posted inNephrology news Rheumatology

Predicting Two-Year Relapse Risk in ANCA-Associated Vasculitis: Insights from the PEXIVAS Trial

Posted by By MedXY 10/02/2026
A risk prediction model derived from the PEXIVAS trial estimates the 2-year relapse probability in ANCA-associated vasculitis, integrating clinical and laboratory factors to improve individualized patient management.
Read More
  • Clesrovimab for Prolonged Protection Against Severe RSV in High-Risk Infants: Insights From a Two-Season Randomized Trial
  • Silver Diamine Fluoride: A Breakthrough Noninvasive Therapy for Severe Early Childhood Caries in US Children
  • Persistent High Rates of Head CT in Pediatric Mild Traumatic Brain Injury: Variability Among Hospital Types and Implications for Practice
  • Behavioral Interventions in Pediatric Type 1 Diabetes: Optimizing Glycemic Control Through Family-Centered, Multicomponent Strategies
  • Enhancing Pediatric Literacy Promotion for Latino Families: Efficacy of Text Messaging and Resource Referrals in a 3-Arm Randomized Controlled Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top